Kornimate/medical-research-clean huggingface dataset:
arsenic trioxide in treating patients with stage ivb or recurrent cervical cancer

Conditions: Cervical Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of arsenic trioxide in treating patients who have stage ivb or recurrent cervical cancer.

objectives: * evaluate the efficacy of arsenic trioxide in patients with stage ivb or recurrent cervical carcinoma. * determine the safety of this treatment in these patients. outline: patients receive arsenic trioxide iv over 1-4 hours on days 1-5. courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 12-37 patients will be accrued for this study over 10-19 months.

Eligibility criteria:
disease characteristics: * histologically confirmed stage ivb or recurrent cervical carcinoma that is not amenable to standard curative therapies * squamous carcinoma or * adenocarcinoma * measurable disease * at least 20 mm by conventional techniques or * at least 10 mm by spiral ct scan * nonmeasurable disease defined as any of the following: * bone disease * leptomeningeal disease * ascites * pleural/pericardial effusion * inflammatory breast disease * lymphangitis cutis/pulmonis * abdominal masses not confirmed or followed by imaging techniques * cystic lesions * no active brain metastases patient characteristics: age: * 17 and over performance status: * karnofsky 60-100% life expectancy: * greater than 3 months hematopoietic: * absolute neutrophil count at least 1,500/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 1.5 times upper limit of normal (uln) * ast and alt no greater than 2.5 times uln renal: * creatinine no greater than 2.0 mg/dl or * creatinine clearance at least 50 ml/min cardiovascular: * no cardiac arrhythmias, unstable angina, or conduction abnormalities * no new york heart association class iii or iv heart disease or clinical evidence of congestive heart failure * pretreatment qtc less than 500 msec other: * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception during and for 4 months after study * no grade 3 or greater neurologic abnormalities * no history of seizures * no concurrent uncontrolled active infection prior concurrent therapy: biologic therapy: * no more than 2 prior therapies for advanced disease chemotherapy: * no more than 2 prior therapies for advanced disease * at least 4 weeks since prior chemotherapy endocrine therapy: * no more than 2 prior therapies for advanced disease radiotherapy: * no more than 2 prior therapies for advanced disease * at least 4 weeks since prior radiotherapy surgery: * not specified other: * at least 4 weeks since prior cytotoxic therapy or investigational agents

Keywords: recurrent cervical cancer stage ivb cervical cancer cervical squamous cell carcinoma cervical adenocarcinoma
improving gait performance in individuals with spinal cord injuries: an intervention using robotic exoskeletons

Conditions: Spinal Cord Injuries

Summary: the purpose of this study is to investigate whether robotic exoskeleton training can improve walking performance after sci as compared to conventional physical therapy.


Eligibility criteria:
inclusion criteria: * motor incomplete spinal cord injury, as classified by american spinal injury association guidelines, above the lumbar level (t12 and above). * able to independently stand for two minutes with or without an assistive device and with or without orthoses distal to the knee. * male or non-pregnant woman * ≥ 18-years of age * at least 6 months after injury * height between 5'2" and 6'2" (150-188 cm) * weight ≤ 220 pounds (100 kg) * ability to perform informed consent exclusion criteria: * presence of clinical signs of lower motor neuron injury * history of severe neurologic injuries other than sci (ms, cp, als, tbi, cva, etc.) * severe comorbidities: active infections, heart, lung, or circulatory conditions, pressure ulcers. * documented severe osteoporosis affecting the hip and spine * severe spasticity in the lower extremities (modified ashworth ≥ 3) or uncontrolled clonus * unstable spine * unhealed limb or pelvic fractures * skin issues that would prevent wearing the device * range of motion restrictions that would prevent subject from achieving a normal, reciprocal gait pattern, or would restrict a subject from completing normal sit to stand or stand to sit transitions. * upper extremity strength deficits that limit ability to balance with a front rolling walker or crutches. * heterotopic ossification that resists functional range of motion in lower extremities * contractures (\>15 degrees at the hips or \>20 degrees at the knees) * psychiatric or cognitive comorbidities resulting in motor planning or impulsivity concerns * colostomy * have received any physical therapy intervention within 3 months prior to enrolment in the study * non-english speaking
e-cigarettes for harm reduction among smokers with serious mental illness

Conditions: Cigarette Smoking

Summary: in this open-label, randomized controlled trial study, participants who smoke combustible cigarettes (cc) and are diagnosed with serious mental illness (smi) will be randomized in two arms to receive harm-reduction counseling and ecological momentary intervention text messaging (emi) along with either e-cigarettes (ec) or nicotine replacement therapy (nrt) such as patch and lozenges to compare the efficacy in cc smoking reduction.


Eligibility criteria:
inclusion criteria: * currently smokes 5 or more cpd * willingness and ability to provide informed consent * age of at least 21 years * has smi diagnosis (such as schizophrenia, schizoaffective disorders, bipolar disorder, depressive disorders, trauma and stressor related disorders etc.) as determined using the mini tool * interested in reducing cc smoking but not necessarily trying to quit * own a mobile phone or have regular access to a mobile phone * able to provide an additional contact to improve follow-up rates exclusion criteria: * is pregnant or breastfeeding * used tobacco other than cc in the past 2 weeks (e.g., ec, cigarillo) * currently engaged in an attempt to quit cc * change in dose of their psychotropic medication(s) in the last 30 days * meeting dsm-v criteria for current alcohol or substance use disorder except for nicotine use disorder and active mild alcohol or substance use disorders. * past month suicidal ideation/suicide attempt and/or psychiatric hospitalization in the last 30 days

Keywords: e-cigarettes harm reduction cigarette smoking serious mental illness
the effect of a developed perioperative rehabilitation pathway following lumbar arthrodesis

Conditions: Physical Disability; Low Back Pain, Recurrent; Surgery

Summary: to compare the current rehabilitation pathway with the implementation of a newly developed rehabilitation pathway for patients with a single and double level lumbar arthrodesis.

this involves a prospective interventional study with a one year follow-up. the investigators will compare the outcomes of the current rehabilitation pathway with a newly developed (based on systematic review and delphi study) rehabilitation pathway for patients with a single and double level lumbar arthrodesis. the usual care group (n= 30) will be compared with the intervention group (n= 30).

Eligibility criteria:
inclusion criteria: * lumbar single and double level arthrodesis * signed informed consent * posterior lumbar interbody fusion (plif), posterolateral lumbar fusion (plf) and transforaminal lumbar interbody fusion (tlif) exclusion criteria: * previous arthrodesis in the lumbar spine * musculoskeletal disorders which interfere with functional outcome, f.e. severe lower limb problems not related to the lumbar surgery * presence of one of the following pathologies:parkinson multiple sclerose (ms), cerebral vascular accident (cva), peripheral neuropathies, circulatory disorders, gout, rheumatoid disorders, neoplasia, septic arthritis, pregnancy, vestibular disorder, infectious diseases * accident at work or lawsuit * low cognition * not able to speak dutch
the siberia trial (acculink™ versus cguard™)

Conditions: Patients With Aterosclerotic Carotid Stenosis; Symptomatic Patients (Stenosis > 50%); Asymptomatic Patients (Stenosis ≥80%)

Summary: that the study will be carried out as it has the protocol instructions, respecting the applicable regulations for clinical investigations with medical devices and following the internationally accepted ethical standards

independent randomized trial in carotid artery revascularization comparing the stent (acculink™) versus the mesh covered stent (cguard™) was performed. ischemic lesions of brain after cas were determined by mri before and after treatment (2-3 days, 1 month).

Eligibility criteria:
inclusion criteria 1. consecutive patients 45-80 years old accepted for cas following neurological consultation and qualification for the procedure according to center's routine practice. 2. more than 6-month life expectancy 3. suitable clinical conditions for performing dw-mri 4. written informed consent approved by the ethics committee 5. subject agrees to all required follow-up procedures and visits exclusion criteria: 1. currently enrolled in another investigational device or drug study that has not completed the study or that clinically interferes with the current study endpoints 2. recent surgical procedure within 30-days before or planned surgery within 30-days after the stenting procedure 3. hepatic active disease (bilirubin\> 35 mmol / l) or renal insufficiency (serum creatinine \> 2.5 mg/dl or glomerular filtration rate \<60 ml / min) 4. recent evolving acute stroke within 30-days of study evaluation 5. myocardial infarction within 72 hours prior to carotid stenting procedure (cpk-mb \> 3 times normal) 6. female patients of childbearing potential or known to be pregnant 7. any known factor for potential stroke other than carotid stenosis, such as atrial fibrillation or atrial flutter (paroxysmal, permanent or persistent) or thrombophilia 8. patient on vka or new oral anticoagulants
biomarker of diabetic retinopathy

Conditions: Diabetic Retinopathy

Summary: diabetic retinopathy (dr) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. this can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen/nutrient deficiency. ultimately affecting the normal vision. there is no known marker that will provide information on the health status of retinal blood vessels. using highly specialized cells in the blood, this study will try to discover a marker of dr.


Eligibility criteria:
inclusion criteria: * ability to cooperate with imaging procedures. * health status: established type 2 diabetes * no history of panretinal photocoagulation (prp) * no history of treatment with intravitreal agents for past 12 months exclusion criteria: * previous or current malignancy * acute or chronic infection (hiv, hepatitis b or c, tuberculosis) * cerebral vascular accident or cerebral vascular procedure * current pregnancy * history of organ transplantation * presence of a graft (to avoid any effect of the graft) * history of previous vitrectomy * subjects with a history of age-related macular degeneration age-related macular degeneration (amd), glaucoma, uveitis, and branched or central vein occlusion.
mihs emergency department cpr quality improvement project

Conditions: Cardiac Arrest

Summary: the investigators will quantify the quality of chest compressions provided in the emergency department and determine whether the quality of chest compressions is related to patient outcome. the quality of chest compressions and patient outcomes will be assessed both before and after the introduction of audiovisual feedback in real time.

the emergency department will be using e-series unit manufactured by zoll medical group (chelmsford, ma). these units are equipped with an accelerometer-based system that allows for measurement of chest compression depth and rate. these units are also equipped with realcprhelp, and fda-approved technology that provides real-time audiovisual feedback to providers on the quality of chest compressions. in the first phase of the project, the ed providers will utilize the e-series units to treat all patients requiring chest compressions.

Eligibility criteria:
inclusion criteria: * 18 years old or older exclusion criteria: * less than 18 years old

Keywords: cardiac arrest, cpr, quality improvement
role of oral care in prevention of nosocomial pneumonia among copd patients

Conditions: Nosocomial Pneumonia; COPD Exacerbation

Summary: poor dental hygiene has been linked to respiratory pathogen colonization in icu patients. therefore, respiratory pathogens tend to colonize dental plaque and oral mucosa in these populations. therefore, strategies to eliminate respiratory pathogens from the oral cavity may improve oral hygiene and decrease the development of nosocomial pneumonia.

infection is a common problem and a major cause of morbidity and mortality for patients in intensive care units (icus). pneumonia is the most common site of infection according to an international study of the prevalence and outcomes of infection in icus, which included 13,796 patients. nosocomial pneumonia (np) is among the leading causes of mortality in patients in the icu. notably, the incidence of nosocomial pneumonia is increasing, and the number of infection-related deaths that follow is also increasing. thus, preventing nosocomial pneumonia is a cost reducing and life-saving health care practice, especial in icus. nosocomial pneumonia (np) was defined as an infection of the lower respiratory tract that does not exist at the time of admission and does not have an incubation period of infection but occurs 48 hours after admission. the most important cause for the development of nosocomial pneumonia is the oral environment. the oral cavity of icu patients is an important reservoir for bacteria and provides a habitat for microorganisms that can lead to nosocomial pneumonia. patients in icus acquire pneumonia by aspirating oral bacteria that have been colonized in the oral cavity into the lower respiratory tract. due to advanced age, limited mobility, illness, and cognitive dysfunction, patients in icus often have difficulty maintaining oral hygiene by themselves. poor dental hygiene has been linked to respiratory pathogen colonization in icu patients. therefore, respiratory pathogens tend to colonize dental plaque and oral mucosa in these populations. therefore, strategies to eliminate respiratory pathogens from the oral cavity may improve oral hygiene and decrease the development of nosocomial pneumonia. the aim of the present study is to assess value of preventive strategy using chlorhexidine for oral care among non-intubated copd patients admitted to icu upon incidence of nosocomial pneumonia.

Eligibility criteria:
inclusion criteria: * patients diagnosed as copd * admitted to icu with acute exacerbation * need for noninvasive ventilatory support including noninvasive ventilation anf high flow nasal cannula exclusion criteria: * patients refusing to participate * end stage organ failure (heart failure, liver cell failure and/or renal failure

Keywords: copd oral care nosocomial pneumonia chlorhexidine
open label ruxolitinib (incb018424) in patients with myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis

Conditions: Myelofibrosis; Polycythemia Vera; Thrombocytosis

Summary: to determine the safety, tolerability and effectiveness of ruxolitinib (incb018424), administered orally to patients with primary myelofibrosis (pmf), post polycythemia vera myelofibrosis (ppv-mf) and essential thrombocythemia myelofibrosis (pet-mf).

this is a multicenter, open-label, non-randomized, dose escalation study of ruxolitinib, a small molecule janus kinase (jak) inhibitor, administered orally to patients with pmf, ppev-mf or pet-mf. the study is comprised of 3 parts: part 1: dose escalation and determination of maximum tolerated dose (complete). part 2: exploration of alternative dosing schedules (complete). part 3: further evaluation of selected dose regimens, including additional response measures to explore effect of ruxolitinib on symptoms and other parameters including daily physical activity and long-term survival (ongoing).

Eligibility criteria:
inclusion criteria: * diagnosed with pmf or post-pv/et mf * patients with myelofibrosis requiring therapy * adequate bone marrow reserve exclusion criteria: * received anti-cancer medications or investigational therapy in the past 14 days
the incidence, effect and persistence of fragmented-qrs, in patients presenting with st-elevation myocardial infarction

Conditions: ST Elevation Myocardial Infarction

Summary: this study will assess the incidence, effect and persistence of f-qrs (fragmented-qrs) in stemi (st-elevation myocardial infarction) patients post-pci (percutaneous coronary intervention). the aim is to add to the existing research field surrounding f-qrs. it is hypothesised that patients with f-qrs present on the surface ecg, following pci, will have incurred a higher degree of damage. as a result, it is hypothesised that these patients will have reduced lv (left-ventricular) systolic function, increased incidence of regional wall motion abnormalities (rwmas), and increased troponin levels on admission. this study will additionally look for correlations between f-qrs and culprit vessels. to our knowledge there is minimal research regarding this.

this is a physiological - retrospective data collection from stemi patients. data from 100 stemi patients treated with primary pci will be extracted. data will be collected from presentation / initial admission, 6-week post-mi (myocardial infarction) clinic and 6 month post-mi clinic from the hospital system at new cross hospital. data from admission includes; 12-lead ecg, echo reports and blood test results. additionally, the 12-lead ecgs undertaken at 6-week and 6-months will be assessed for the presence of f-qrs.

Eligibility criteria:
inclusion criteria: * look back to data at least 12 months old in order to ensure 6-week and 6-month follow up data is available. the inclusion criteria will be patients that presented with stemi and were treated with primary pci. exclusion criteria: * from the cath lab reports and clinical letters exclusions apply to patients that did not present with stemi. in addition, patients that were not treated with primary pci, or patients that deceased prior, during or post procedure (during hospitalization).
integrative multi-omics testing for immunotherapy response in non-small cell lung cancer

Conditions: Lung Cancer

Summary: the objective of this study is to use blood and urine proteomic and metabolomic features to monitor lung cancer immunotherapy response.

observational, ambispective single-center cohort study, including 400 patients with locally advanced unresectable or metastatic nsclc who received or are receiving immunotherapy in routinely clinical practice. for the part of retrospective study，the investigators intend to include 200 patients who received immunotherapy at nanfang hospital from january 1, 2020 to march 1, 2023. for the part of prospective study，the investigators intend to include 200 patients who will receive immunotherapy at nanfang hospital from march 1, 2023 to december 31, 2025.

Eligibility criteria:
inclusion criteria: 1. patients who are 18 years or older at the time of signing the informed consent form; 2. patients with histologically or cytologically confirmed non-small cell lung cancer that is metastatic or locally advanced unresectable, not eligible for local curative treatment (stage iiib or iv according to ajcc); 3. patients without contraindications for immunotherapy according to csco guidelines for non-small cell lung cancer (nsclc) version 2022（no egfr mutations, alk or ros1 rearrangement); 4. patients with at least one measurable lesion according to the response evaluation criteria in solid tumors \[recist\], version 1.1; 5. patients who have not received systemic treatment in the past, or who have previously received (neo) adjuvant treatment/radical treatment programs and have relapsed for more than 6 months; 6. patients who signed the informed consent and are willing to participate in the study. exclusion criteria: 1. patients with the history of autoimmune disease or immunodeficiency disease; 2. any severe, uncontrolled diseases, including: (1) active or uncontrolled heart diseases, (2) renal failure requires hemodialysis or peritoneal dialysis; (3) liver diseases such as liver cirrhosis, decompensated liver disease, chronic active hepatitis; 3. any severe, uncontrolled urological diseases, or urine total protein \>1.0g/day. 4. any severe, uncontrolled metabolic diseases, including uncontrolled diabetes mellitus (fasting blood glucose (fbg)\>10mmol/l);

Keywords: non-small cell lung cancer immunotherapy blood proteomic blood metabolomic urine proteomic urine metabolomic monitoring of immunotherapy response multi-omics